Natsuaki M, Morimoto T, Yamamoto E, et al. - Since there is a lack of a prospective inquiry assessing 3-month dual antiplatelet therapy (DAPT) following cobalt-chromium everolimus-eluting stent (CoCr-EES) implantation in patients with acute coronary syndrome (ACS), researchers assessed 3-month DAPT duration in all-comer population following CoCr-EES implantation in a prospective multi-center single-arm study, named the STOPDAPT trial. ACS patients (N = 487) and stable coronary artery disease (CAD) patients (N = 1,038) were compared in terms of 1-year clinical results. A composite of cardiovascular mortality, myocardial infarction, stroke, definite stent thrombosis (ST) and TIMI major/minor bleeding was considered as the primary endpoint. The ACS and stable CAD groups did not differ significantly in terms of cumulative 1-year incidence of and the adjusted risk for the primary endpoint. No definite/probable ST through 1-year was identified in both groups. Overall, findings revealed that in ACS patients including 47% of unstable angina, stopping DAPT at 3 months following CoCr-EES implantation was as safe as that in those with stable CAD.